COG AALL1521: A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Objective

This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.

https://clinicaltrials.gov/ct2/show/NCT02723994

Location: Essentia Health Cancer Centers

Research Study Categories

• Pediatric Studies

Specialty

• Hematology

Contact

Cancer Clinical Trials at 844-681-7944
or cancertrials@essentiahelath.org